Exelixis
- Market cap
- 14.48B
- P/E (TTM)i
- 18.38
- P/Bi
- 7.85
- EPSi
- 2.78
- Div yieldi
- 0.00%
- 52W posi
- 90%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Fair Value how this is computed
- Implied fair-value range of 38.60-123.07, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -27.7% below the average-multiple fair value of 80.84.
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Exelixis (EXEL) | 14.48B | 18.38 | 7.85 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 128.16B | 29.45 | 6.33 | 0.00% |
| Moderna (MRNA) | 78.44B | -24.62 | 11.60 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 76.40B | 18.36 | 2.41 | 0.49% |
| argenx SE (ARGX) | 58.39B | 35.37 | 6.94 | 0.00% |
| Revolution Medicines (RVMD) | 43.05B | -22.65 | 16.52 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 5.8% above Morningstar's fair value estimate.
Fair value
Exelixis Inc is assigned a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 6% premium over our quantitative fair value estimate of $55.03 per share; however, this estimate should be taken with a pinch of salt due to its medium uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The firm's valuation metrics decrease our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to market value ratio of 1.0, which sits in the bottom 40% globally. The market value of equity makes up a large fraction of enterprise value, indicating that shares have sharply risen, or that the company has a "lazy" balance sheet that is underleveraged. We believe this is a sign that shares could be overvalued.
Conversely, the company's balance sheet is reassuring. Low leverage mitigates financial risk, potentially boosting a firm's value. The firm's current ratio of 3.5, a core component of leverage, lies in the top 30% compared with peers globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which, despite our unfavorable price/fair value ratio, is a positive attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.
By Quantitative Equity Report
Quote time 2026-10-08 07:38:54 · For reference only, not investment advice and not tailored to your situation.